| Filed On | Filing |
|---|---|
| 21 Sep 2026 | SCHEDULE 13G |
| 17 Sep 2026 | SCHEDULE 13D/A |
| 17 Sep 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Acquired 9,078,529 Pre-Funded Warrants (Right to Buy) (Open Market Purchase) ($200M) |
| 17 Sep 2026 |
Form 4: Harris Todd, Director
Received 864 shares as a grant or award ($7.89K) |
| 17 Sep 2026 |
Form 4: Rueb Yuliya, Vice President, Finance (PAO)
Received 2,925 shares as a grant or award ($26.7K) |
| 17 Sep 2026 |
Form 4: Fuhrman Alan, Chief Financial Officer
Received 951 shares as a grant or award ($8.68K) |
| 17 Sep 2026 | SCHEDULE 13G |
| 15 Sep 2026 | 424B5 |
| 15 Sep 2026 |
8-K: Other Events
Tyra Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co., Barclays Capital Inc. and each of the other Underwriters named in Schedule A ... |
| 14 Sep 2026 | FWP |
| 14 Sep 2026 | S-3ASR |
| 11 Sep 2026 |
Form 4: Verjee Rehan, Director
Bought 971.8943 shares ($20K) |
| 09 Sep 2026 |
8-K: Other Events
On September 9, 2026, Tyra Biosciences, Inc. (TYRA or the Company) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade inter... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 04 Aug 2026 | 424B5 |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jul 2026 | SCHEDULE 13G |
| 26 Jun 2026 | 144 |
Loading...
